Pf267 Risk Assessment of Anthracycline Cardiotoxicity in Patients With Acute Leukemia and Concomitant Ischemic Heart Disease

Abstract

detected in two ED patients (1 HR and 1 IR patients), which was the same mutation NRAS G12C. FLT3 gene mutations (including FLT3-ITD and FLT3-TKD) were the most frequently found in HR APL patients. 88.33% of HR patients(10/12) harbored FLT3 mutations, while 20% of IR patients (5/25) and 22.22% of LR patients (2/9) were found harbored FLT3 mutations(P < 0.05). Among the 17 cases of FLT3 mutant patients, only one HR patient (5.88%, 1/17), who carried FLT3-TKD D835Y mutation, died 3 days after induction treatment. Meanwhile, the less common WT1 gene mutations were all found in IR APL patients. Summary/Conclusion: HR APL patients had the highest frequency of gene mutations, however there were no significant difference between the three risk groups regarding the median mutation numbers. ED patients did not have more gene mutations compared with non-ED patients. FLT3 gene mutations were the most frequently occurred mutations, especially in HR APL patients, though might have no relation with early mortality.

Effects of high-intensity interval training on vascular function in breast cancer survivors undergoing anthracycline chemotherapy: design of a pilot study

“… 8 During anthracycline intercalation, oxidative stress is caused by the increased production of reactive oxygen species (ROS), which disrupts the regulation of nitric oxide, a major vasodilator. 9 The bioavailability of nitric oxide is reduced due to anthracycline-generated ROS that scavenge the nitric oxide. This aspect of vascular endothelial dysfunction results in reduced brachial artery flow-mediated dilation (baFMD) and thickening of the carotid intima media (cIMT), both of which can be assessed via ultrasound imaging.…”